Immunome's Q4: A Miss, But the Real Story is What's Priced In for 2026

The numbers are in, and they confirm a miss. For the fourth quarter, Immunome reported an earnings per share of -$0.75, missing the consensus estimate of -$0.60 by a significant 25%. Revenue was $0, a sharp decline from the same period last year's $2.74 million. On the surface, this looks like a negative surprise. Yet the real question for investors is whether this miss was a new, alarming signal or simply the latest in a pattern the market has already priced in.

The context is crucial. This isn't the first time the stock has reacted poorly to a miss. In the previous quarter, a smaller EPS shortfall led to a 1.68% drop in the share price the following day. That sets a clear expectation: the market has a low tolerance for negative surprises from this cash-burning biotech. Given that the company has consistently reported losses, with Q4's -$0.75 actually being less severe than the -$1.28 it posted a year ago, the miss may have been within a range of outcomes the street anticipated. The bigger shock was the revenue collapse to zero, which the company itself noted was a non-cash period. This framing suggests the top-line drop was a timing or accounting quirk, not a fundamental business failure.

So, the expectation gap here is narrow. The miss was real, but not catastrophic. The stock's muted reaction-likely already reflecting a high bar for perfection-points to a market that has been braced for disappointment. The investment thesis now pivots away from this quarterly print. The real story is what happens next: the company's cash runway and the potential catalysts that could reset the narrative for 2026.

The Pipeline Catalysts: What's Priced In for 2026?

The market's focus has shifted from the Q4 miss to the 2026 catalysts that could reset the narrative. The primary expectation gap now centers on the regulatory path for varegacestat, the company's lead asset. After a positive Phase 3 RINGSIDE readout, the plan is clear: submit a New Drug Application to the U.S. Food and Drug Administration for varegacestat in the second quarter of 2026. This creates a high bar. The stock's trajectory hinges on whether this submission leads to approval, which would validate the entire clinical program and provide a much-needed commercial endpoint. Anything less-delays, requests for additional data, or a rejection-would be a severe disappointment given the significant investment already made.

Beyond varegacestat, the pipeline expansion signals a potential de-risking of the ADC platform. The company plans to submit INDs for three differentiated solid tumor ADCs in 2026, a move that diversifies the story away from a single asset. This is a strategic reset, aiming to build a broader portfolio. The early clinical activity for the IM-1021 ADC program provides a near-term data catalyst, with initial data expected in 2026 and objective responses already observed. This activity offers tangible proof of concept for the HC74 payload, which is designed to overcome resistance mechanisms that plague other ADCs.

The bottom line is that the market is pricing in a binary outcome for varegacestat. The cash position, extended to 2028 after a recent capital raise, provides the runway to see this through. But the stock's volatility will be dictated by the execution of these 2026 milestones. A successful NDA submission and positive early ADC data would narrow the expectation gap, potentially unlocking value. Any stumble, however, would likely widen it further, as the market has already discounted a high probability of disappointment from this cash-burning biotech.

The Financial Foundation: Cash Runway and Guidance

The financial setup is the critical buffer for this high-stakes 2026. After a December public offering raised $460.5 million in gross proceeds, the company's cash runway is now projected into 2028. This is a direct response to the market's expectation of deep, sustained losses. Analyst consensus sees FY2025 EPS at -$2.21, with losses continuing through 2027 before turning positive in 2028. The cash raise effectively funds the path to the 2026 catalysts, removing near-term dilution risk from cash burn.

This creates a clear expectation gap. The market has already priced in years of heavy losses. The new capital doesn't change that trajectory; it simply extends the timeline for when the company needs to achieve a commercial endpoint. The strategy is to fund operations through the pipeline, with the varegacestat NDA submission as the primary near-term milestone. The runway provides the luxury of time to execute that plan without the pressure of a looming cash crunch.

The bottom line is one of managed risk. The losses are expected and the cash is there to cover them. The real investment question isn't about sustainability-it's about timing. The market has discounted the burn, but it is now betting that the 2026 catalysts will be enough to reset the valuation. Any delay or setback in the pipeline could force a reassessment of that timeline, but for now, the financial foundation is solid enough to support the wait.

Catalysts, Risks, and What to Watch

The investment thesis now hinges on a handful of specific events that will either close or widen the expectation gap. The primary watch item is the topline data release for the RINGSIDE trial, which is expected before the end of this year. This data will confirm the Phase 3 readout and set the stage for the next major milestone: the New Drug Application submission for varegacestat in the second quarter of 2026. The market has priced in a high bar for this submission. The real test comes after that, when the FDA reviews the application. The key risk is that the NDA could face regulatory hurdles, requiring additional data or facing a delay, which would directly challenge the binary approval timeline the stock is now betting on.

On the positive side, the ADC platform offers a parallel catalyst. The Phase 1 trial of IM-1021 is ongoing, and the company expects to present initial data for that program in 2026. Positive early clinical activity here would de-risk the entire ADC platform, demonstrating the potential of the HC74 payload. This could attract partnership interest and diversify the story away from a single asset, potentially unlocking value even if the varegacestat path faces delays.

The bottom line is that the coming months will be defined by execution against this 2026 timeline. The cash runway provides the time, but the stock's volatility will be dictated by the successful delivery of these catalysts. Any stumble in the pipeline could force a reassessment of the timeline, but for now, the financial foundation is solid enough to support the wait.